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Juvenile (23 years old) cynomolgus monkeys are frequently used as recipients in non-human primate islet transplantation 
studies. The aim of this study was to examine the effects of different doses of streptozotocin (STZ), and find the optimal dose 
for inducing diabetes in these monkeys. Fifteen juvenile (23 years old) cynomolgus monkeys were separated into three 
groups and administered with different doses of STZ (100, 68 or 60 mg kg1). Basal and glucose-stimulated blood glucose, in-
sulin, and C-peptide levels, as well as body weights were monitored. Hepatic and renal function tests and pancreatic immuno-
histochemistry were performed before and after STZ treatment. Monkeys treated with both 100 and 68 mg kg1 of STZ exhib-
ited continuous hyperglycemia, which coincided with a nearly complete loss of islet -cells. Two monkeys received 60 mg 
kg1 of STZ, but only one became completely diabetic. During the first week following STZ treatment, hepatic and renal func-
tion slightly increased in these three groups. However, 24 hours post-STZ, serum total bile acid levels were significantly in-
creased in monkeys treated with 100 mg kg1 than those treated with 68 mg kg1 of STZ (P<0.05). These data suggest that 100 
mg kg1 and 68 mg kg1 of STZ can safely induce diabetes in cynomolgus monkeys aged 23 years, but 68 mg kg1 of STZ, 
rather than 100 mg kg1 of STZ, may be more appropriate for inducing diabetes in these monkeys. Furthermore, body surface 
area, rather than body weight, was a more reliable determinant of dosage, where 700 mg m2 of STZ should be the lower limit 
for inducing diabetes in juvenile monkeys. 
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Insulin-dependent diabetes mellitus (IDDM) is a type of 
metabolic disease caused by the destruction of insulin- pro-
ducing pancreatic cells. IDDM has serious effects on pa-
tients and could result in many severe complications, in-
cluding end-stage renal failure, blindness, and non-   
traumatic amputations. Although exogenous insulin injec-
tions can save lives, they cannot cure diabetes. In recent  
years, pancreatic islet transplantation and stem cell therapy 
have proven to be promising approaches for restoring the 
physiological secretion of insulin in IDDM patients [15]. 
However, before these approaches can be developed into 
clinically viable treatments, many important issues need to 
be resolved, such as the limited sources of human islets for 
cell-based diabetes therapies, the stability of functional al-
pha- and beta-cell masses, the safety of stem cell therapies 
for diabetes mellitus [68]. Precise and reliable animal 
models of diabetes mellitus would thus be very important in 
resolving these problems. 
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Animal models of diabetes mellitus include spontaneous 
and induced diabetic models. Spontaneous diabetic models 
are primarily rodents (e.g., non-obese diabetic mice, Bi-
obreeding rats, Otsuka Long-Evans Tokushima Fatty rats, 
etc.) [911], and have been used in elucidating the genetics 
and pathophysiology of diabetes mellitus. However, the 
genetics, pathology, and physiology of rodents are very dif-
ferent from humans, suggesting that the conclusions drawn 
from these animal models are not fully translatable to hu-
man IDDM. Non-human primates have a close phylogenetic 
and immunological relationship with humans. Therefore, 
they would be especially useful in researching human dia-
betes. While there availability is limited, spontaneous dia-
betes has also been reported in non-human primates [1214]. 
Models of induced diabetes are primarily drug-induced (e.g., 
streptozotocin (STZ) and alloxan) or achieved with a pan-
createctomy. However, these methods have respective dis-
advantages. For example, the pancreatectomized animal 
models require a daily administration of oral pancreatic en-
zymes to maintain normal digestive function, which could 
be dangerous and complex for the handler. The beta-cell 
toxin, alloxan, is chemically unstable, as it has a very short 
half-life and rapidly decomposes into non-diabetogenic 
alloxanic acid in aqueous solution [15]. Additionally, the 
diabetogenic dose of alloxan has a narrow range, and a 
slight overdose may be lethal [16]. Although alloxan-   
induced diabetic monkeys have been reported in previous 
studies [17,18], alloxan is currently used to induce IDDM 
primarily in rodents and rabbits. STZ, derived from Strep-
tomyces acbromogenes, is a commonly used diabetogenic 
toxin, which selectively kills insulin-producing cells, and 
has been widely used in IDDM induction in rodents, mon-
keys, and other animals. Previous studies reported that a 
single administration of 150 or 55 mg kg1 of STZ can con-
sistently, reliably, and safely induce IDDM in 68 month or 
36 year-old cynomolgus monkeys, respectively [19,20]. 
Cynomolgus monkeys have been frequently used as recipi-
ents in nonhuman primate islet transplantation studies due 
to their ease of handling and readiness for transplantation 
[2124]. However, the optimal dosage for IDDM induction 
in juvenile (23 years old) cynomolgus monkeys is still 
unclear. Additionally, other studies have also suggested that 
the genus and age of monkeys have an important effect on 
their sensitivity to STZ [25,26]. Therefore, in the present 
study, we characterized the induction of stable IDDM in 
juvenile cynomolgus monkeys (23 years old) using three 
different doses of STZ, in hopes of finding an optimal dose 
that produces minimal hepatic and renal toxicity. 
1  Materials and methods 
1.1  Animals 
Fifteen male cynomolgus monkeys (23 years old; 2.74.1 
kg), which were free of Mycobacterium tuberculosis, Shi-
gella, Salmonella, Helminths, Ectoparasites, Entamoeba 
histolytica and herpes B virus, were used in this study. An-
imal care and use were conducted at the Primate Research 
Center of Wincon TheraCells Co. in Nanning, China (an 
AAALAC accredited facility), under the guidance of the 
Animal Laboratory Protocol established by the Guangxi 
Bureau of Science and Technology and approved by the 
Institutional Animal Care and Use Committee (IACUC). 
Monkeys were reared in individual cages in the same room 
with other animals. Ambient temperature in the room was 
kept at 25°C, and humidity was set between 40% and 70%. 
The air was replaced 12 times hourly. Lights were on for 12 
h, from 07:30 to 19:30. All animals had a continuous water 
supply and were fed with the same commercially prepared 
monkey food, plus fruits twice daily. The animals were 
conditioned for a minimum of 1 month prior to the start of 
the experiment. 
1.2  Induction of diabetes with STZ 
All monkeys were fasted for 1215 h prior to receiving STZ, 
which was administered under anesthesia with ketamine (10 
mg kg1 of body weight) and atropine (0.04 mg kg1). 
One-hundred mg of STZ (Sigma-aldrich, Saint Louis, MO) 
was dissolved into 50 μL of 0.05 mol L1 citric acid (pH 4.5) 
and 5 mL of saline, and then diluted into 20 mL (final vol-
ume) of saline at 4°C [24]. Immediately after dissolving, 
100 (n=7), 68 (n=6), and 60 (n=2) mg kg1 of STZ were 
administered via the saphenous vein over a 5-minute period. 
Diabetic monkeys were treated with two injections of insu-
lin per day to prevent metabolic dysfunction. Insulin doses 
were determined via previously determined scale, which is 
as follows: glucose levels < 11.1 mmol L1 = no insulin; 
glucose levels between 11.116.6 mmol L1 = 12 U of 
insulin; glucose levels between 16.622.2 mmol L1 = 24 U 
of insulin; and glucose levels > 22.2 mmol L1 = 46 U of 
insulin [19]. 
1.3  Metabolic studies 
Blood glucose levels were monitored twice daily during the 
first week after the STZ injection, and twice daily every 
Monday and Thursday thereafter, using a Roche Glucotrend 
monitor. An intravenous glucose tolerance test (IVGTT) 
was performed one month after the STZ injection. Briefly, 
glucose (0.5 g kg1 of body weight) was injected into the 
saphenous vein of the animal through a 24-gauge catheter. 
Blood glucose levels were recorded at 0, 3, 5, 10, 20, 30, 
and 60 min with a Roche Glucotrend monitor. Plasma was 
collected at 0, 10, 20, and 30 min for insulin and C-peptide 
measurements. K value, representing the rate of glucose 
disappearance, was calculated using the following formula: 
K=69.3/t1/2, where t1/2 equals the time required for the glu-
cose concentration to be halved. 
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1.4  Blood chemistry 
For hepatic and renal function tests, serum was collected 
before, and 24 h, 72 h, one week, and one month after STZ 
administration. The following parameters were measured 
using an automatic analyzer (7170, Hitachi, Tokyo, Japan): 
alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), total bile acid (TBA), cholinesterase (CHE), lactate 
dehydrogenase (LD), adenosine deaminase (ADA), blood 
urea nitrogen (BUN), and creatinine (Cr). 
1.5  Body weight and surface area measurements 
Cynomolgus monkeys were weighed before, and one and 
five weeks after STZ administration. Monkeys were trans-
ferred by a carrier and weighed on a weight scale. The body 
surface area (m2) was calculated from the body weight (g) 
using the following formula: surface area=body weight0.67 × 
12/10000. 
1.6  Immunohistochemical staining 
Normal pancreatic tissue was obtained from an autopsy 
from five male cynomolgus monkeys (23 years old). These 
animals were used for other experiments and were healthy 
at sacrifice. Diabetic pancreatic tissue was obtained from a 
pancreatectomy performed on the diabetic animals 23 
months after the STZ injection. Pancreatic tissue was fixed 
in 4% paraformaldehyde, embedded in paraffin, and cut into 
5 µm thick sections. Paraffin sections were stained using an 
immunofluorescent technique to visualize β- and α-cells. 
Briefly, the sections were dewaxed with xylene and ethanol, 
blocked with 1% bovine serum albumin at room tempera-
ture for 1 h, then incubated with primary antibodies over-
night at 4ºC. The primary antibodies were guinea pig an-
ti-human insulin (1:100; Zymed, San Francisco, CA) and 
mouse anti-human glucagon (1:1000; Sigma-Aldrich, Saint 
Louis, MO). The sections were then incubated with Texas 
red-conjugated donkey anti-guinea pig IgG or Cy2-conju- 
gated goat anti-mouse IgG (1:200; Jackson Immu-
noResearch, Baltimore, PA). Fluorescent images were cap-
tured using a Nikon 2000U microscope and SPOT RT cam-
era. The final images were rendered via Adobe Photoshop. 
1.7  Morphological examinations 
The entire pancreatic area, islet area, and number of β- and 
α-cells were determined via immunofluorescent staining. 
For each pancreas, six sections (>50 μm apart) were exam-
ined. 
1.8  Statistical analysis 
For all comparisons, P<0.05 was considered statistically 
significant. Results were expressed as means±SD or mean 
(range), and groups were compared with ANOVA or non-
parametric tests. 
2  Results 
Following the STZ injection, blood glucose levels in all 
groups were monitored continuously. Blood glucose levels 
were measured at pre-STZ injection, and 6, 20, and 28 h 
post-STZ injection. Corroborating previous studies [25,27], 
a representative triphasic blood glucose response to STZ 
was observed in monkeys treated with 100 mg kg1 (STZ 
100) and 68 mg kg1 (STZ 68) of STZ (7.5 mmol L1 at 6 h 
post-STZ, followed by 1.5 mmol L1 at 20 h post-STZ, and 
8 mmol L1 at 28 h post-STZ). However, the insulin-   
dependent monkey treated with 60 mg kg1 of STZ (STZ 
60-ID) did not exhibit the above mentioned blood glucose 
response. In the STZ 60-ID monkey, there was no profound 
hypoglycemia detected and its blood glucose levels gradu-
ally increased to >11.1 mmol L1 by day 4 post-STZ. These 
responses were different in other STZ-treated monkeys that 
required insulin to prevent ketoacidosis (STZ-ID), since 
their blood glucose levels were promptly augmented on the 
second day post-STZ. Table 1 summarizes the metabolic 
parameters before and after STZ treatment. Following the 
STZ injection, all animals in the STZ 60-ID, STZ 68, and 
STZ 100 groups exhibited hyperglycemia, with mean fast-
ing blood glucose levels >22 mmol L1. There were no sig-
nificant differences in the post-STZ blood glucose levels 
between the STZ 68 and STZ 100 groups. Additionally, the 
IVGTT findings suggest significant evidence of impaired 
carbohydrate tolerance in all three groups (K<0.6). Moreo- 






IVGTT K  
value 
IVGTT 
Basal values of  
insulin (mU L1) 
Basal values of  
C-peptide (pmol L1) 
Peak values of  
insulin (mU L1) 
Peak values of  
C-peptide (pmol L1) 
Normal (Pre-STZ) 15 2.4±0.4 3±0.4 3.96±1.73 19(0125) 447(1801555) 147(36200) 1657(6242987) 
STZ 60-NID 1 5.7 5.9 1.44 14.7 413 43.7 590 
STZ 60-ID 1 26.4 28.1 0.33 1.1 28 1.9 28 
STZ 68 6 22.1±4.9** 24.7±1.4** 0.34±0.08** 1.5 (0.73.8)** 0.4 (02)** 1.7 (0.83.8)** 3(015)** 
STZ 100 7 26.5±3.2** 27.2±3.5** 0.37±0.22** 0.8 (03.2)** 8 (025)** 0.9 (03.2)** 9 (031)** 
a) Data are expressed as mean±SD or means (range). **, P<0.01 vs. normal (pre-STZ). 
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ver, almost no circulating C-peptide and insulin could be 
detected after STZ treatment, and all diabetic animals in the 
three groups needed a subcutaneous injection of exogenous 
insulin (810 U d1) to avoid metabolic dysfunction. How-
ever, the mean fasting blood glucose level increased to only 
5.7 mmol L1 in the non-insulin independent monkey treat-
ed with 60 mg kg1 of STZ (STZ 60-NID). IVGTT findings 
demonstrated that peak C-peptide levels decreased from 
2582 to 590 pmol L1, and peak insulin levels decreased 
from 200 to 43.7 mU L1. This indicated that this monkey 
did not require daily exogenous insulin injections. 
Immunohistochemistry revealed that, while glucagon ex-
pression was persistent in the remaining islets of both the 
STZ 100 and STZ 68 groups, insulin expression had disap-
peared (Figure 1). Morphometric analyses showed that the 
islet area in relation to the total pancreatic area in both the 
STZ 68 and STZ 100 groups decreased by 40%50% com-
pared with the control group. However, the difference did 
not reach statistical significance (P=0.055) (Figure 2A). 
When β-cell numbers were expressed per islet area or total 
pancreatic area, there was a significant decrease compared 
with the control group (P<0.05) (Figure 2B and C). In con-
trast, α-cell numbers per islet area in the STZ 68 and STZ 
100 groups were significantly increased compared with the 
control group (P<0.05) (Figure 2D). However, α-cell num-
bers per total pancreatic area did not change significantly 
compared with the control group (P>0.05) (Figure 2E). Ad-
ditionally, morphometric findings in the STZ 60-ID monkey 
were similar to those of the STZ 68 and STZ 100 groups. 
However, β-cell numbers per islet area and total pancreatic 
area decreased to 17% and 5%, respectively, from normal 
control values in the STZ 60-NID monkey. Moreover, the 
spatial frequency of α-cells in the diabetic and normal islets 
also demonstrated a distinguishable difference. In normal 
islets, α-cells were scattered throughout the islets, whereas 
in the diabetic islets, these glucagon positive cells over-
whelmingly occupied the entire islet. 
The findings of the hepatic and kidney function tests at 
various time points after an administration of 60, 68 and 
100 mg kg1 of STZ are presented in Table 2. Serum ALT, 
AST, and TBA values in STZ 100, STZ 68, and STZ 60-ID 
were slightly elevated within one week post-STZ. At one 
month post-STZ, a further increase in serum ALT, AST, 
and TBA values was detected. Conversely, while serum 
ALT, AST, and TBA values in the STZ 60-NID monkey 
also increased slightly at 24 to 72 h after the STZ injection, 
these values returned to near-normal levels within one week 
post-STZ. Moreover, BUN levels were slightly increased 
within the first 24 h, and recovered to normal within one 
month in STZ 100, STZ 68, and STZ 60-ID, whereas STZ 
60-NID had normal kidney function after the STZ injection. 
No treatment-related changes were observed in other hepatic  
 
 
Figure 1  Immunostaining of islets from normal (A, E, I, M), STZ 100 (B, F, J, N), STZ 68 (C, G, K, O), and STZ 60-NID (D, H, L, P) monkeys. Insulin 
expression had disappeared, whereas glucagon expression appeared to be augmented in STZ 100 and STZ 68 groups. In contrast, there were still a few insu- 
lin-positive cells remaining in the islets of the STZ 60-NID group. Scale bar, 50 µm. 
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Figure 2  A, Islet area in relation to the entire pancreatic area. B, Number of β-cells per islet area. C, Number of β-cells per the entire pancreatic area. D, 
Number of α-cells per islet area. E, Number of α-cells per entire pancreatic area in the control group (n=5) and 60 mg kg1 (n=2), 68 mg kg1 (n=5), and 100 
mg kg1 (n=5) STZ-treated groups. 
and renal parameters measured. 
The body weights of all monkeys were measured at the 
first and fifth week after STZ administration to test whether 
the STZ injection would dramatically decrease their body 
weights in the short term, as previously described in 
STZ-treated mice. Figure 3A reveals that the STZ 60-ID 
monkey had an apparent loss in body weight (up to 15%) 
one week post-STZ, whereas the body weight of the STZ 
60-NID monkey remained steady throughout the five weeks 
after the STZ treatment. The monkeys in the STZ 68 and 
STZ 100 groups had stable body weights during the first 
week post-STZ, and lost about 10% (not significant) of 
body weight by the fifth week post-STZ (Figure 3B and C). 
3  Discussion 
Animal models of IDDMs, particularly non-human primates,  
are important for developing therapeutic strategies for 
IDDM. Different STZ administration protocols have been 
used to induce diabetes in cynomolgus and rhesus monkeys. 
The findings of these studies suggest that different species 
and ages of monkeys respond differently to STZ treatment. 
Shibata et al. tested three different doses of STZ in adult 
rhesus monkeys (2.57.5 years old), and found that 125 mg 
kg1 of STZ could reliably induce diabetes without any risk, 
whereas 100 mg kg1 of STZ failed to induce IDDM and 
two of the seven animals died within 7 h following an ad-
ministration of 150 mg kg1 of STZ [25]. In another study, 
Thomas et al. found that all juvenile (23 years old, 3.13.8 
kg) male rhesus macaques given 140 mg kg1 of STZ de-
veloped type 1 diabetes, and this dose was not fatal [26]. 
These diabetic animals were maintained for >1 year, and no 
reversal of type 1 diabetes was observed [26]. Koulmanda et 
al. examined the effect of low versus high doses of STZ in 
cynomolgus monkeys (36 years old, 3.19 kg) to deter-
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mine the optimal dose necessary to reliably induce diabetes 
with minimal toxicity. It was found that 55 mg kg1 of STZ 
successfully induced diabetes in cynomolgus monkeys with 
minimal hepatic and renal toxicity, whereas animals treated 
with higher doses were found to have hepatic and renal 
damage [20]. Conversely, Thieriault et al. showed that 150 
mg kg1 of STZ consistently induced diabetes in juvenile 
cynomolgus monkeys (68 months old, 12 kg) with mini-
mal morbidity and no fatalities [19]. 
We examined the diabetogenic and adverse effects of 
STZ in juvenile cynomolgus monkeys (23 years old, 
2.74.1 kg) using three different doses (60, 68, and 100 
mg kg1) to also determine the optimal dose for inducing 
diabetes. Various parameters that are associated with a 
diabetic states, including blood glucose, plasma insulin 
and C-peptide, and hepatic and kidney functioning, were 
monitored prior to and after inducing diabetes in these 
animals. Our findings revealed that 68 and 100 mg kg1 of 
STZ successfully induce a stable diabetic state, and one 
out of two animals receiving 60 mg kg1 of STZ developed 
hyperglycemia. All STZ-induced diabetic animals in STZ 
100, STZ 68, and STZ 60-ID groups maintained hyper-
glycemia for >8 months, and no reversal of hyperglycemia 
was observed (Figure 4). Blood glucose levels were con-
sistent with the pancreatic immunohistochemistry findings, 
where there was a nearly complete loss of β-cells in all  
 
 
Figure 3  Body weights before, and one and five weeks after STZ treatment. A, 60 mg kg1. B, 68 mg kg1. C, 100 mg kg1 groups. STZ 60-ID monkeys 
presented with an apparent loss in body weight (up to 15%) in the first week post-STZ, whereas STZ 60-NID, STZ 68, and STZ 100 monkeys did not 
demonstrate any changes in body weight in the first week post-STZ. With the exception of STZ 60-NID, by week 5 post-STZ, the body weights of all mon- 
keys decreased by 10% compared with pre-STZ body weights, although the difference was not significant (P>0.05). 
 
Figure 4  Fasting and non-fasting glucose levels in a representative monkey from each group, STZ 100 (■), STZ 68 (◆), STZ 60-ID (▲), and STZ 60-NID 
(*) are shown in panels A and B, respectively. All monkeys that received 100 and 68 mg kg1 STZ exhibited hyperglycemia within two days of injection, and 
the fasting and non-fasting blood glucose levels increased to >11.1 mmol L1. Furthermore, there was no reversal of hyperglycemia observed throughout the 
long-term follow-up study. However, blood glucose levels of the STZ 60-ID monkey did not increase to >11.1 mmol L1 until day 5 post-STZ, and the STZ  
60-NID monkey never developed hyperglycemia. 
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Time after streptozotocin administration 
  24 h 72 h 1 week 1 month 
STZ 60 ALT mean 34 63 61 88 89 
(n=2) (U L1) range (27,41) (52,73) (55,66) (78,98) (37,140) 
STZ 68  mean 35 62* 69* 87* 199** 
(n=6)  range (1650) (4084) (5281) (57156) (74534)
STZ 100  mean 26 40 54 46 120 ** 
(n=7)  range (751) (14100) (24114) (3767) (36314)
STZ 60 AST mean 38.5 65.5 39 51 85 
(n=2) (U L1) range (30,47) (48,83) (36,42) (44,58) (28,141) 
STZ 68  mean 39 58* 41 54 160** 
(n=6)  range    (3384) (45357)
STZ 100  mean 41 63 77* 61 134* 
(n=7)  range (2272) (27115) (47167) (3394) (41225)
STZ 60 TBA mean 3 7.4 4.3 4.4 11.5 
(n=2) (µmol L1) range (3,) (7.4,) (4.3,) (4.4,) (11.5,)
STZ 68  mean 3 12.5* 10.7 5.9* 23.5** 
(n=6)  range (1.84.8) (2-20.2) (0.4-19.9) (2.7-8.5) (10.133.9)
STZ 100  mean 2.2 40.6**† 32.4** 13 21.8** 
(n=7)  range (0.28.3) (4.672.6) (1.384.6) (0.142.8) (6.965.5)
STZ 60 CHE mean 10416 10757 11879 11742 16194 
(n=2) (U L1) range (9129,11703) (9051,12462) (9743,14014) (10219,13265) (11081,21306) 
STZ 68  mean 11239 11875 12795 14733* 14879* 
(n=6)  range (921114138) (1003414804) (1070117145) (1240919562) (1224621093)
STZ 100  mean 12499 12927 13584 17474 18060 
(n=7)  range (646420879) (666419881) (731820361) (1156221935) (1110023816)
STZ 60 LD mean 316 459 414 495 300 
(n=2) (U L1) range (286,346) (541,377) (378,449) (404,585) (289,310) 
STZ 68  mean 355 624 472 404 515 
(n=6)  range (218512) (3321383) (2501100) (261630) (1991153)
STZ 100  mean 445 496 409 392 355 
(n=7)  range (2251208) (2951204) (326529) (363454) (198682)
STZ 60 ADA mean 24 28 22 20 29 
(n=2) (U L1) range (17,31) (20,35) (16,27) (15,25) (19,39) 
STZ 68  mean 26 29 25 23 27 
(n=6)  range (1542) (2049) (1343) (1039) (1738)
STZ 100  mean 27 26 26 24 27 
(n=7)  range (1938) (1842) (1946) (1733) (1743)
STZ 60 BUN mean 7.52 7.5 7.51 11.75 11.59 
(n=2) (mmol L1) range (8.77,6.26) (7.42,7.57) (4.07,10.94) (4.45,19.05) (7.4,15.78) 
STZ 68  mean 7.22 9.95* 8.32 9.13 8.89 
(n=6)  range (5.349.5) (7.4812.65) (7.639.3) (6.5914.39) (4.6913.53)
STZ 100  mean 6.68 8.62* 8.56 9.21 9.04* 
(n=7)  range (5.418.32) (5.9612.65) (6.6110.99) (5.514.06) (6.2211)
STZ 60 Cr mean 58 54 66 92 53 
(n=2) (µmol L1) range (53,63) (51,56) (55,77) (61,123) (67,39) 
STZ 68  mean 58 60 61 60 40** 
(n=6)  range (5364) (5470) (4475) (4290) (3149)
STZ 100  mean 68 66 63 80 62 
(n=7)  range (5682) (4987) (5074) (44132) (25123)
a) Data are expressed as means (range). *, P<0.05 vs. basal; **, P<0.01 vs. basal; †, P<0.05 vs. STZ 68. 
diabetic animals after STZ treatment. However, while the 
STZ 60-NID monkey never became diabetic, the number 
of β-cells decreased to 5% of the normal control after STZ 
treatment. This finding suggests that the compensatory 
activation of the remaining β-cells may lead to the produc-
tion of sufficient amounts of insulin. Thus, a >95% reduc-
tion in the number of β-cells may be necessary for the on-
set of hyperglycemia in cynomolgus monkeys that are 23 
 Zou C L, et al.   Sci China Life Sci   March (2012) Vol.55 No.3 217 
years of age. 
While Koulmanda et al. reported that 55 mg kg1 of STZ 
was sufficient to consistently induce diabetes in cynomol-
gus monkeys [20], our results showed that one of two mon-
keys receiving 60 mg kg1 of STZ failed to lose all β-cell 
function and subsequently become diabetic. The reason for 
this discrepancy may be the age of the monkeys. Koulman-
da et al. used older monkeys, which were 36 years old, 
whereas we used younger monkeys, which were 23 years 
old. The islets of younger non-human primates may be more 
resistant to destruction, and thereby may influence the dose 
of STZ required to induce diabetes. However, it is still un-
clear why only one of the two monkeys of the same age 
became diabetic after receiving 60 mg kg1 of STZ. We 
speculate that different body weights (2.9 and 3.9 kg) may 
be a reason for this dichotomy. Wijkstrom et al. suggested 
that the dose of STZ depends on body surface area rather 
than body weight [28]. We found that the dosages were dif-
ferent on an mg m2 basis between the STZ 60-NID and 
STZ 60-ID monkeys, although both received the same dose 
(60 mg kg1) on an mg kg1 basis (Table 3). Additionally, 
by extrapolating our data, it was found that a dose >760 mg 
m2 of STZ may reliably induce IDDM in cynomolgus 
monkeys 23 years old of age, whereas a dose <700 mg m2 
of STZ is not effective. 
The adverse effects of STZ mainly include hepatic and 
renal injury. Although the indices of hepatic and renal func-
tion (i.e., ALT, AST, TBA, and BUN) in the STZ 68 and 
STZ 100 groups were slightly elevated within one week 
post-STZ, the above indexes were still in the near-normal 
range. Our results differ from those of Koulmanda et al., 
who reported that 100 mg kg1 of STZ markedly elevated 
liver and renal function values in monkeys post-STZ. One 
reason for this may be that younger animals have a higher  
threshold of sensitivity to STZ, as the previous studies de-
scribed [19]. In addition, most of the 23 year-old monkeys 
used in our study had stable body weight post-STZ, whereas 
Koulmanda et al. reported a rapid loss in body weight of up 
to 20% in the 36 year-old monkeys receiving either a high 
or low dose of STZ. These findings further suggest that 
younger monkeys have a more stable metabolism and re-
sistance to STZ than older monkeys. One month post-STZ, 
the ALT, AST, and TBA levels were further increased, 
likely due to the adverse effects of hyperglycemia than the 
direct damage induced by STZ. Thus, diabetic models can 
be reliably induced in juvenile cynomolgus monkeys (23 
years old) with either 68 or 100 mg kg1 of STZ without 
marked hepatic or renal impairment. However, we also 
noted that serum TBA levels had significantly increased in 
the STZ 100 than STZ 68 group at 24 h after the STZ injec-
tion. However, there were no significant differences in se-
rum ALT and AST between the two groups (Table 2). This 
suggests that 100 mg kg1 of STZ in 23 year-old cyno-
molgus monkeys may result in slightly more severe hepatic 
damage than 68 mg kg1 of STZ, since serum TBA is more 
sensitive than AST in determining the severity of liver dis-
ease [29]. 
In conclusion, juvenile cynomolgus monkeys (23 years 
old) are more tolerant to STZ than older cynomolgus mon-
keys of previous studies. Therefore, diabetes can be induced 
in these monkeys with either a 68 or 100 mg kg1 STZ in-
jection without any marked hepatic or renal impairment, but 
a low dose of STZ (68 mg kg1) may be more appropriate. 
Less than 60 mg kg1 of STZ does not appear to reliably 
induce diabetes in 23 year-old cynomolgus monkeys. Fur-
thermore, STZ dosing should be based on body surface area 
rather than body weight, with 700 mg m2 of STZ being the 
lower limit for inducing IDDM in 23 year-old cynomolgus 
monkeys. 
Table 3  Comparison of streptozotocin dosing using body weight versus body surface area 
Group Animal ID BW (kg) STZ (mg kg1) Total STZ (mg) Surface area (m2) STZ (mg m2) 
STZ 60-ID 0511971 3.9 60 234 0.3056 766 
STZ 60-NID 0202673 2.9 60 174 0.2506 694 
       
 0301001 3.38 68 229.8 0.2777 827.7 
 0302001 4.1 68 278.8 0.316 882.3 
STZ 68 0504411 2.86 68 194.4 0.2483 783.2 
 0504409 2.8 68 190.4 0.2448 777.8 
 0503008 2.7 68 183.6 0.2389 768.5 
 0504425 3.15 68 214.2 0.2649 808.6 
       
 0201077 3.3 100 330 0.2733 1207.5 
 0208529 3.2 100 320 0.2677 1195.4 
 0101535 3.2 100 320 0.2677 1195.4 
STZ 100 0012041 4.1 100 410 0.316 1297.5 
 0012033 3.05 100 305 0.2592 1176.7 
 0108127 3.3 100 330 0.2733 1207.5 
 0401739 2.8 100 280 0.2448 1143.8 
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